论文部分内容阅读
随着艾滋病的蔓延,出现了各种治疗药物。就目前已被批准为抗艾滋病的药物来说,都是等待病毒在细胞内发作后,才开始采取行动。现在研究人员正在研制一种新药,可以像保安在门口阻止讨厌的不速之客那样,在病毒侵入细胞之前,就使它无法动弹。 16位人体免疫缺损病毒呈阳性,但没有任何艾滋病症状的成人,接受了这种还处于试验阶段的药物——T-20的静脉注射,每天两次,共两周。注射量最高的4位病人,其艾滋病病毒的浓度降低了99％,其效果与现在给艾滋病患者服用的组合药物一样。美国研究过敏症及传染病的专家认为,T-20药物的抗病毒效果出乎人们预想的结果。但是人们对此项目的热诚,并不仅仅是为了一种新药,而是为了获得一种全新的治疗方法。
With the spread of AIDS, a variety of therapeutic drugs have emerged. For drugs currently approved as anti-AIDS, all wait for the virus to begin to take action before it starts to attack in the cell. Now researchers are working on a new drug that will prevent the virus from moving before the virus intrudes, just as security guards prevent unpleasant intruders at the door. Twenty-six adults with positive human immunodeficiency virus, but without any AIDS symptoms, received intravenous injection of this yet-to-test drug, T-20, twice daily for two weeks. Four of the highest-injected patients had a 99% reduction in HIV, the same effect as the combination currently administered to AIDS patients. Experts on allergy and infectious diseases in the United States believe that the antiviral effect of T-20 drugs is beyond the expected results. But people’s enthusiasm for this project, not just for a new drug, but to get a brand new treatment.